Human antibody COR-101 neutralizes the coronavirus SARS-CoV-2 with high efficacy in animal model

Braunschweig, December 18, 2020 – YUMAB spin-off CORAT Therapeutics today reports the successful conclusion of hamster disease model tests of their lead candidate COR-101 for the treatement of COVID-19. COR-101 drastically reduced the amount of SARS-CoV-2 in the lung, confirming the excellent neutralization properties of the new agent in a living organism and its ability to prevent disease progression. First clinical tests of COR-101 are in preparation.

Read CORAT’s press release (English)

Read CORAT’s press release (German)


Dr. Thomas Schirrmann, CEO
Phone: +49-531 481170-0

CORAT Therapeutics GmbH
Dr. Andreas Herrmann, Managing Director
Phone: +49-152 2404 7488